DYN
Dyne Therapeutics, Inc.
$23.74
+1.02
(+4.49%)
Mkt Cap
3.92B
Volume
1,537,919
52W Range
8.88-25
Sector
Healthcare
Beta
1.06
EPS (TTM)
-3.22
P/E Ratio
-5.64
Revenue (TTM)
0
Rev Growth (5Y)
N/A
EPS Growth (5Y)
N/A
Company Description
Dyne Therapeutics, Inc. is a U.S.-based biotechnology firm focused on developing advanced treatments for genetically driven muscle disorders. Utilizing its proprietary FORCE platform, which is engineered to deliver disease-modifying therapeutics, the company is actively engaged in various programs. These initiatives target conditions such as myotonic dystrophy type 1, Duchenne muscular dystrophy, and facioscapulohumeral dystrophy, in addition to other rare skeletal, cardiac, and metabolic muscle diseases. The company was founded in 2017 and maintains its corporate headquarters in Waltham, Massachusetts.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 506.00M | 1.37B | 842.00M | 1.47B |
| Net Income | (446.21M) | (317.42M) | (235.94M) | (168.10M) | (149.29M) | (58.74M) | (13.54M) | (4.81M) | 76.00M | (1.24B) | 50.00M | (67.00M) |
| EPS | -3.47 | -3.37 | -3.95 | -3.23 | -2.93 | -1.24 | -0.30 | -0.47 | 0.47 | -9.61 | 0.40 | -0.53 |
| Free Cash Flow | (405.13M) | (294.75M) | (188.89M) | (156.71M) | (123.18M) | (47.67M) | (13.48M) | (4.30M) | 361.00M | 350.00M | (181.00M) | (62.00M) |
| FCF / Share | -3.15 | -3.13 | -3.16 | -3.02 | -2.42 | -1.01 | -0.30 | -0.42 | 2.23 | 2.71 | -1.45 | -0.49 |
| Operating CF | (403.21M) | (292.37M) | (188.16M) | (153.65M) | (119.56M) | (46.51M) | (11.83M) | (4.16M) | 585.00M | 676.00M | 94.00M | (62.00M) |
| Total Assets | 1.19B | 691.23M | 165.08M | 306.32M | 425.66M | 353.33M | 16.44M | 8.27M | 11.77B | 13.05B | 11.54B | 11.23B |
| Total Debt | 20.28M | 23.99M | 27.41M | 30.48M | 32.64M | 0 | 0 | 3.38M | 8.43B | 8.98B | 7.29B | 7.11B |
| Cash & Equiv | 893.37M | 435.45M | 121.63M | 172.15M | 200.82M | 300.85M | 14.63M | 8.12M | 365.00M | 1.78B | 505.00M | 1.87B |
| Book Value | 972.13M | 629.84M | 91.29M | 252.36M | 368.20M | 342.37M | 14.04M | (4.88M) | 1.90B | 2.04B | 2.92B | 3.02B |
| Return on Equity | -0.46 | -0.50 | -2.58 | -0.67 | -0.41 | -0.17 | -0.96 | N/A | 0.04 | -0.61 | 0.02 | -0.02 |
| Metric | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | (120.85M) | (111.95M) | (108.04M) | (110.86M) | (115.36M) | (89.54M) | (97.12M) | (65.10M) | (65.65M) | (66.64M) | (60.21M) | (64.90M) |
| EPS | -0.73 | -0.76 | -0.76 | -0.97 | -1.05 | -0.88 | -0.96 | -0.70 | -0.81 | -1.09 | -0.99 | -1.08 |
| Free Cash Flow | (145.14M) | (112.32M) | (109.96M) | (94.76M) | (106.87M) | (85.41M) | (74.88M) | (55.73M) | (78.73M) | (35.09M) | (50.77M) | (55.89M) |
| FCF / Share | -0.88 | -0.87 | -0.78 | -0.83 | -0.97 | -0.84 | -0.74 | -0.60 | -0.97 | -0.57 | -0.83 | -0.93 |
| Operating CF | (144.92M) | (111.83M) | (90.78M) | (94.70M) | (105.89M) | (84.33M) | (74.63M) | (54.87M) | (78.54M) | (35.01M) | (50.60M) | (55.64M) |
| Total Assets | 1.08B | 1.19B | 867.06M | 728.99M | 721.07M | 691.23M | 768.84M | 825.88M | 522.28M | 165.08M | 205.24M | 251.42M |
| Total Debt | 19.30M | 20.28M | 120.47M | 121.08M | 23.33M | 23.99M | 24.86M | 25.72M | 26.62M | 27.41M | 28.23M | 29.04M |
| Cash & Equiv | 753.10M | 893.37M | 573.61M | 485.04M | 472.25M | 435.45M | 532.16M | 608.20M | 272.04M | 121.63M | 130.28M | 167.61M |
| Book Value | 865.05M | 972.13M | 691.78M | 571.45M | 668.97M | 629.84M | 705.54M | 775.19M | 478.06M | 91.29M | 152.04M | 206.88M |
| Return on Equity | -0.14 | -0.12 | -0.16 | -0.19 | -0.17 | -0.14 | -0.14 | -0.08 | -0.14 | -0.73 | -0.40 | -0.31 |
DYN News
Dyne Therapeutics vs. Recursion Pharmaceuticals: Which Development Stage Pharma Stock Is a Better Buy in 2026?
Dyne Therapeutics vs. Vertex Pharmaceuticals: Which Drug Innovator Stock Is a Better Buy in 2026?
Dyne Therapeutics vs. Viking Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?
Biotech ETF Index Surges 10% After Rebalance
Dyne Therapeutics Appoints Barry Greene to Board of Directors
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Dyne Therapeutics Announces Expanded Debt Facility of Up To $400 Million with Hercules Capital, Inc.
Dyne Therapeutics Announces Completion of Enrollment in Registrational Expansion Cohort of ACHIEVE Trial of Z-Basivarsen for Myotonic Dystrophy Type 1 (DM1)
Dyne Therapeutics Stock Gains 4.5% After BLA Filing for DMD Therapy
Dyne Therapeutics Announces Submission of Biologics License Application (BLA) to U.S. FDA for Z-Rostudirsen in Exon 51 Duchenne Muscular Dystrophy (DMD)